Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
British Virgin IslandsIPO:
02 January 2002Website:
http://www.portagebiotech.comNext earnings report:
28 November 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | 27 min agoDividend
Analysts recommendations
Institutional Ownership
What type of business is Portage Biotech?
Portage Biotech Inc., a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline comprises PORT-8, a dual inhibitor of adenosine receptors 2A and 2B, which is in preclinical trial to treat solid tumors; PORT-9, an A2B antagonist, which is in pre-clinical stage program to treat colorectal and gastrointestinal cancers; and PORT-3, a polylactide-co-glycolide, which is in phase 1 to treat NY-ESO-1 positive tumors. The company also develops PORT-4, a nanolipogel co-formulations to treat of solid tumors that is in preclinical trials; and PORT-5, a VLP-STING to treat of solid tumors and is in preclinical trials. Portage Biotech Inc. is based in Tortola, British Virgin Islands.
What sector is Portage Biotech in?
Portage Biotech is in the Healthcare sector
What industry is Portage Biotech in?
Portage Biotech is in the Biotechnology industry
What country is Portage Biotech from?
Portage Biotech is headquartered in British Virgin Islands
When did Portage Biotech go public?
Portage Biotech initial public offering (IPO) was on 02 January 2002
What is Portage Biotech website?
https://www.portagebiotech.com
Is Portage Biotech in the S&P 500?
No, Portage Biotech is not included in the S&P 500 index
Is Portage Biotech in the NASDAQ 100?
No, Portage Biotech is not included in the NASDAQ 100 index
Is Portage Biotech in the Dow Jones?
No, Portage Biotech is not included in the Dow Jones index
When was Portage Biotech the previous earnings report?
No data
When does Portage Biotech earnings report?
The next expected earnings date for Portage Biotech is 28 November 2024